Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
N4 Pharma ( (GB:N4P) ) just unveiled an update.
N4 Pharma has announced a collaboration with the University of Strathclyde’s CMAC National Facility to advance its Nuvec® delivery platform. This partnership aims to accelerate the development of Nuvec® towards clinical readiness and explore its broader therapeutic applications, leveraging CMAC’s expertise in drug delivery and pharmaceutical manufacturing. The collaboration is expected to strengthen N4 Pharma’s commercial data package and enhance its positioning as a leading gene delivery platform, potentially unlocking new possibilities in RNA therapeutics.
More about N4 Pharma
N4 Pharma plc is a UK-based biotechnology company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company is positioned within the biotech industry, emphasizing gene delivery platforms for nucleic acid therapies.
Average Trading Volume: 1,350,989
Technical Sentiment Signal: Sell
Current Market Cap: £7.62M
See more insights into N4P stock on TipRanks’ Stock Analysis page.